Johnson & Johnson raised full-year 2026 guidance after adjusted earnings per share beat expectations at $2.90.
Johnson & Johnson reported second-quarter adjusted earnings per share of $2.90, surpassing the $2.85 estimate, as revenue climbed 6.6% to $25.31 billion. Net earnings reached $5.53 billion, or $2.27 per share, with adjusted net earnings up 5.7% to $7.08 billion.
The Innovative Medicine segment led growth, rising 7.8% to $16.38 billion, while MedTech sales increased 4.5% to $8.93 billion. Tremfya sales surged 72.5% to $2 billion, offsetting patent expirations on older drugs like Stelara.
JNJ raised its 2026 guidance, now expecting sales of $100.8 billion to $101.4 billion and adjusted EPS of $11.60 to $11.75, up from prior projections.